[at Forbes] – Investors in Celgene Corp. (NASD: CELG) saw new options begin trading today, for the November 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CELG options chain for the new November 29th contracts and identified one put and one call contract of particular interest. The […]
Read more on this.
Celgene Corporation (CELG), with a current market cap of $64.69B, began trading this morning at $158.89.
A quick look at the market, the company’s traded between $156.04 to $160.00 with its 52-week range being $71.23 to $161.64.
Celgene (CELG) shares are currently priced at 26.76x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -17.51x earnings multiple for the same period.
Consensus earnings for the current quarter by the 25 sell-side analysts covering the stock is an estimate of $1.54 per share, which would be $0.25 better than the year-ago quarter and a $0.03 sequential increase. Furthermore, our analysis shows the full-year EPS estimate to be $5.98, which would be a $1.07 better when compared to the last year’s annual results.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $1.64 Billion. If reported, that would be a 15.49% increase over the year-ago quarter.
In terms of ratings, Argus upgraded CELG from Hold to Buy (Jun 13, 2013).
Previously, Deutsche Bank upgraded CELG from Hold to Buy.
When considering if the stock is under or overvalued, the average price target is $157.13, which is 1.11% below where the stock opened this morning.
Celgene Corporation (NASDAQ:CELG), discovers, develops and commercializes therapies for cancer and immune-inflammatory related diseases in the US and Europe. It has strategic collaborations with bluebird bio, FORMA Therapeutics, Concert Pharmaceuticals, Array BioPharma, Acetylon Pharmaceuticals, PharmAkea Therapeutics, and a strategic alliance with MorphoSys AG.
Tag Helper ~ Stock Code: CELG | Common Company name: Celgene | Full Company name: Celgene Corporation (NASDAQ:CELG) .